---
title: Mounjaro Can Now Be Prescribed to Lower Heart Attack and Stroke Risk in Type 2 Diabetes
description: The FDA cleared Mounjaro to lower cardiovascular risk in adults with type 2 diabetes, based on a trial where it matched an older heart-protective drug.
author: Darie Nani (Editor-in-Chief)
date: 2026-08-29T09:30:00.000Z
updated: 2026-08-29T10:40:29.060Z
canonical: https://richhealthmagazine.com/article/mounjaro-cardiovascular-risk-fda-approval
image: https://cdn.nanimediahouse.com/pexels-a-doctor-uses-a-stethoscope-on-a-smiling-patient-in-a-bright-5215023.jpg
categories: science & tech, Health
content_type: News
region: United States
publication: Rich Health Magazine
access: members
schema_type: Article
---

The FDA has approved Mounjaro to reduce the risk of cardiovascular death, heart attack, and stroke in adults with type 2 diabetes who are at high risk for those events. For the many people who already take the once-weekly injection to manage their blood sugar, the same medicine now carries a formal, FDA-backed reason to expect some protection for the heart as well.

The new use is written for a specific group. It covers adults with type 2 diabetes who face a high risk of a cardiac event, and the clearest evidence behind it comes from people who already have cardiovascular disease. It is not a heart claim for everyone who takes the drug.

That evidence comes from a study called SURPASS-CVOT, which enrolled 13,299 adults who had both type 2 diabetes and established atherosclerotic cardiovascular disease, and followed them for a median of about four years. Rather than comparing Mounjaro to a dummy injection, the trial tested it head to head against dulaglutide, sold as Trulicity, an older Lilly drug that already lowers cardiac risk. Over the study, a major cardiovascular event occurred in [12 percent of the people taking Mounjaro and 13 percent of those taking dulaglutide, a difference that met the statistical bar for non-inferiority but did not reach significance for superiority](https://www.acc.org/latest-in-cardiology/journal-scans/2026/01/07/14/20/surpass-cvot).

---

*This article is only available to registered readers. Visit the article URL to read the full piece.*